CALR and neoplasm: A recent Phase I trial (NCT03784625) of melanoma-targeted radionuclide therapy showed that [131I]ICF01012 induces immunogenic tumor cell death, marked by a significant increase in cell surface Anxa1 and calreticulin [39].